Host: Jennifer Caudle, DO

Guest: Moti Ramgopal, MD

As a healthcare provider, it can be important to minimize the time between diagnosis and the beginning of therapy for newly diagnosed HIV-1 patients. That’s why infectious disease specialist Dr. Moti Ramgopal explains how SYMTUZA® can help us close the gap between those two crucial points of a HIV-1 care and be a treatment option when rapididly initiating patients.

INDICATION

SYMTUZA® is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults:

• who have no prior antiretroviral treatment history or
• who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B

• Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF) and may occur with discontinuation of SYMTUZA®.

  Action: Monitor hepatic function with both clinical and laboratory follow-up for at least several months in ...